- JP-listed companies
- Renascience Inc.
- Cash flow
Renascience Inc. (4889) Cash flow
Market cap
¥18.4B
P/E ratio
-53.3x
Rena Science develops pharmaceuticals, medical devices, and AI-powered software to address critical health challenges including cancer, diabetes, and age-related diseases.
| 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Depreciation & amortization | 3 | 3 | 3 | 1 | 2 | 0 |
| Cash from operations | -178 | -89 | -230 | -285 | -231 | -176 |
| Capital expenditures | - | -1 | -1 | -2 | -2 | -1 |
| Cash from investing | -381 | -2 | -0 | 0 | -2 | 382 |
| Proceeds from issuance of term debt, net | 380 | 96 | 104 | 110 | 47 | 9 |
| Repayments of term debt | - | - | -380 | - | - | -62 |
| Cash from financing | 380 | 136 | 1,592 | 110 | 47 | -52 |
| Free cash flow | - | |||||
| FCF margin (%) | - |